Setback for German Merck's Gastric Cancer Drug

by VR Sreeraman on  July 6, 2012 at 1:47 PM Clinical Trials News   - G J E 4
Germany's Merck KGaA suffered another setback after its gastric cancer drug Erbitux failed to help patients with advanced stomach tumors in a late- stage clinical trial.
 Setback for German Merck's Gastric Cancer Drug
Setback for German Merck's Gastric Cancer Drug

The trials found that in combination with standard chemotherapy, Erbitux did not extend "the length of time that patients live without their disease getting worse," Merck KGaA said in a statement.

"We are disappointed that the ... trial did not show a benefit for patients with advanced gastric cancer when Erbitux was added to standard chemotherapy," said Florian Lordick, in charge of the clinical trials.

"Understandably, these results are disappointing for patients with advanced gastric cancer, and as a company we will continue to invest in oncology research and development to find new treatments for these diseases," said Merck's head of drug development, Annalisa Jenkins.

The results would not alter the proven utility of Erbitux in its already approved indications for metastatic colorectal cancer and head and neck cancer, Merck KGaA said.

The news hit Merck KGaA shares which were showing a loss of 0.38 percent at 79.65 euros in mid-morning trade on the Frankfurt stock exchange in a generally firmer market.

Source: AFP

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like